Precigen, Inc. (Nasdaq: PGEN), a US-vased biopharmaceutical company, announced on Wednesday that it has named Rutul R Shah as its new chief operating officer (COO), effective 1 October 2022.

In the new role, Shah will be responsible for strategic management of the company's portfolio, and ensuring agility and operational efficiency in executing company priorities while collaborating closely with Finance, Business Development and R&D. He will report to the company's president and CEO, Helen Sabzevari, PhD, and serve as a member of Precigen's leadership team.

Shah has held roles of increasing responsibility at Precigen, Inc and most recently served as head of Operations and Portfolio. He has over 17 years of experience in the biopharmaceutical industry and has spent a decade in scientific positions concentrated on the development of protein and antibody drugs at Zyngenia, Teva Biopharmaceuticals USA, CoGenesys, and Human Genome Sciences.